Main Menu

Outset Medical Inc.

(NASDAQ GS: OM)

Rigrodsky Law, P.A. is investigating potential claims against the officers and directors of Outset Medical, Inc. (“Outset Medical” or the “Company”) on behalf of stockholders.

The investigation covers shareholders who purchased or otherwise acquired Outset Medical shares on or before September 15, 2020 and who still hold their shares.

ABOUT THE INVESTIGATION:

The investigation concerns whether Outset Medical and certain of its directors and/or officers issued materially misleading information and/or failed to disclose material information to the investing public. Specifically, the investigation concerns whether Outset Medical and certain of its directors and/or officers failed to disclose to shareholders that: (i) TabloCart, an accessory for the Company’s flagship product, Tablo Hemodialysis System (“Tablo”), required prior clearance from the FDA for marketing authorization, which would require the Company to halt sales of TabloCart until FDA approval was received; (ii) the Company lacked the sales team and process to ramp up sales of Tablo; (iii) Outset Medical marketed its Tablo products for continual renal replacement therapy as a modality even though it was not included in the FDA-approved indications; and (iv) as a result, the Company’s reports and financial statements were not accurate.

THERE IS NO COST TO YOU.

There is no cost to you to join this action. We represent investors on a contingency fee basis. This means that we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees only if we are successful.

If you are interested in joining the action or receiving more information, you may fill out the form below or contact Leah Wihtelin cost free at (516) 693-8926 or by email at lw@rl-legal.com.

Join This Action

Alternatively, you may upload your transactions using the upload button below or email them to info@rl-legal.com.

Draw your signature below using your mouse* [Clear]

Signed pursuant to California Civil Code Section 1633.1, et seq. - and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

Date of signing: 11/13/2024


* Indicates a required field.

Back to Page